Abstract
Purpose
To investigate whether cilostazol, a cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitor, suppresses intimal hyperplasia in canine vein grafts, and to elucidate its mechanisms in terms of cell proliferation and apoptosis.
Methods
Bilateral reversed jugular vein interposition grafts of the common carotid artery were performed in 12 beagle dogs. Starting from 7 days before surgery, either cilostazol (30 mg/day; n = 6) or a placebo (n = 6) was given orally twice daily. Vein grafts were harvested at 1 or 4 weeks, and fixed under pressure for histological examination.
Results
By 1 week after implantation, the cilostazol group showed significantly less cell proliferation than the placebo group. By 4 weeks after implantation, intimal and medial thickness was significantly thinner in the cilostazol group than in the placebo group. There was significantly more apoptosis in the placebo group than in the cilostazol group at both time points.
Conclusion
Cilostazol suppressed the development of intimal hyperplasia in canine autogenous vein grafts. Thus, it may be associated with the modulation of cell proliferation and apoptosis.
Similar content being viewed by others
References
Taylor LM, Edwards JM, Porter JM. Present status of reversed vein bypass grafting: Five-year results of a modern series. J Vasc Surg 1990;11:193–206.
Bergamini TM, Towne JB, Bandyk DF, Seabrook GR, Schmitt DD. Experience with in situ saphenous vein bypasses during 1981 to 1989: Determinant factors of long-term patency. J Vasc Surg 1991;13:137–149.
Donaldson MC, Mannick JA, Whittemore AD. Femoral-distal bypass with in situ greater saphenous vein: Long-term results using the Mills valvulotome. Ann Surg 1991;213:457–464.
Nishi T, Tabusa F, Tanaka T, Shimizu T, Kanbe T, Kimura Y, et al. Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II: 6-[3-(1-Cyclohexyl-5-tetrazolyl)-propoxy]-1,2-dihydro-2-oxoquinoline and related compounds. Chem Pharm Bull 1983;31:1151–1157.
Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung/Drug Res 1985;35:1144–1149.
Tanaka K, Gotoh F, Fukuuchi Y, Amano T, Uematsu D, Kawamura J, et al. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the microcirculation in feline cerebral ischemia. Stroke 1989;20:668–673.
Ikeda U, Ikeda M, Kano S, Kanbe T, Shimada K. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. Eur J Pharmacol 1996;14:197–202.
Kubota Y, Kichikawa K, Uchida H, Maeda M, Nishinine K, Makutani S, et al. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Invest Radiol 1995;30:532–537.
Tsuchikane E, Katoh O, Sumitsuji S, Fukuhara A, Funamoto M, Otsuji S, et al. Impact of cilostazol on intimal proliferation after directional coronary atherectomy. Am Heart J 1998;135:495–502.
Tsuchikane E, Furuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999;100:21–26.
Makutani S, Kichikawa K, Uchida H, Maeda M, Konishi N, Hiasa Y, et al. Effect of antithrombotic agents on the patency of PTFE-covered stents in the inferior vena cava: An experimental study. Cardiovasc Intervent Radiol 1999;22:232–238.
Fuxian Z, Nishibe T, Yasuda K, Yingli J, Changming Z, Zuotian M. Effect of cilostazol on endothelial cell loss and growth in canine vein grafts. Surg Today 2001;31:891–894.
Takai S, Jin D, Nishimoto M, Sakaguchi M, Kirimura K, Yuda A, Miyazaki M. Cilostazol suppresses intimal formation in dog grafted veins with reduction of angiotensin II-forming enzymes. Eur J Pharmacol 2001;411:301–304.
O’Brien JE Jr, Ormont ML, Shi Y, Wang D, Zalewski A, Mannion JD. Early injury to the media after saphenous vein grafting. Ann Thorac Surg. 1998;65:1273–1278.
Hayashi S, Morishita R, Matsushita H, Nakagami H, Taniyama Y, Nakamura T, et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension 2000;35:237–243.
Indorfi C, Di Lorenzo E, Rapacciuolo A, Stingone AM, Stabile E, Leccia A, et al. 8-Chloro-cAMP inhibited smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. J Am Coll Cardiol 2000;36:288–293.
Garg UC, Hassid A. Nitric oxide-generating vasodilator and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat smooth muscle cells. J Clin Invest 1989;83:1774–1777.
Holm AM, Andersen CB, Haunso S, Hansen PR. Effects of Larginine on vascular smooth muscle cell proliferation and apoptosis after balloon injury. Scand Cardiovasc J 2000;34:28–32.
Nishihara H, Hwang M, Kizaka-Kondoh S, Eckmann L, Insel PA. Cyclic AMP promotes CREB-dependent induction of the cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK. J Biol Chem. 2004;279:26176–26183.
Aharoni D, Dantes A, Oren M, Amsterdam A. cAMP-mediated signals as determinants for apoptosis in primary granulosa cells. Exp Cell Res. 1995;218:271–282.
Duprez E, Gjertsen BT, Bernard O, Lanotte M, Doskeland SO. Antiapoptotic effect of heterozygously expressed mutant RI (Ala336→Asp) subunit of cAMP kinase I in a rat leukemia cell line. J Biol Chem 1993;268:8332–8340.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kudo, F.A., Kondo, Y., Muto, A. et al. Cilostazol suppresses neointimal hyperplasia in canine vein grafts. Surg Today 39, 128–132 (2009). https://doi.org/10.1007/s00595-008-3819-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00595-008-3819-2